Patient dies in Neurogene’s Phase I/II Rett syndrome trial
A report filed with a US authority discloses that a patient who suffered a severe adverse event during the trial has now died.
Cytiva-Cell & Gene Therapy WP 2
Purespring secures $105m to start Phase I/II trial of IgAN gene therapy
How will cell & gene therapy manufacturing look in 10 years?
Spur Therapeutics to begin Phase III gene therapy trial in Gaucher disease
Advancing quality control measures vital for cell and gene therapy development
APAC leaps ahead in adoptive cell therapy space
NHS investment critical to drive cell and gene therapy research
Circular RNA: Vaccines, therapeutics and biomarkers could be revolutionised
